The Nikkei share average added 2.4 percent to 20,038.97, rebounding from a sharp 2.3-percent drop on its first trading session this year on...

The STOXX 600 is set for its worst yearly performance since 2008, having fallen more than 13 percent year-to-date.

The broader Topix closed 1.99 percent lower at 1,562.51, its weakest point since May 2017.

The Nikkei share average gained 0.4 per cent to 24,033.79.

The greater the rise, the greater the fall, so they are being targeted as the stocks to short.

India's intellectual property regulations and liabilities laws pose a major barrier to foreign companies, specially from the US, that preve...

Last month Pankaj Patel announced his more than 20-years running the company were over.

The US Court of Appeals for the Federal Circuit has affirmed judgement in favour of Zydus Pharmaceuticals (USA) Inc.

Microsoft’s deal to buy professional social network LinkedIn for $26.2bn officially closed after the European Commission cleared the acquis...

Hyderabad-headquartered Gland is a leading contract manufacturers of injectables, supplying to pharma majors in India and US like Dr Reddy’...

The FTSE 100 index was down 0.8 per cent at 5,909.24 points at its close, underperforming the broader pan-European FTSEurofirst 300.

GKN rose 2.6 per cent, leading the gains in the FTSE 100 , after Credit Suisse raised its price target for the stock to 410 pence from 380 ...

In 2003, Nadathur Holdings, the venture investing arm of NS Raghavan, made its first investment in Connexios, a small drug discovery startu...

Reliance Industries, freed from its non-compete agreement with the Anil Dhirubhai Ambani Group (ADAG) that barred it from investing in high...

The Rs 3,700-crore Zydus Group’s US subsidiary Zydus Pharmaceuticals USA has challenged the Irish company Shire Pharmaceuticals over its pa...

Vincent Aita of Kilkenny Capital Management says he picks biotechnology stocks on their potential as takeover targets.